A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.
Serial analysis for the activating JAK2(V617F) mutation performed in 44 patients with myelofibrosis with myeloid metaplasia showed no interval change in 88% (22/25) of patients over a median interval of 18.6 months. The increase in JAK2 expression observed in three patients did not correspond to disease progression or leukemic transformation.
Ruben A
RA
Mesa
Heather
H
Powell
Terra
T
Lasho
Goron W
GW
DeWald
Rebecca
R
McClure
Ayalew
A
Tefferi
D006801:Humans; D053614:Janus Kinase 2; D008137:Longitudinal Studies; D009154:Mutation; D010649:Phenylalanine / Q000235:genetics; D055728:Primary Myelofibrosis / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000235:genetics*; D015854:Up-Regulation / Q000235:genetics; D014633:Valine / Q000235:genetics
D011518:Proto-Oncogene Proteins; D010649:Phenylalanine; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D014633:Valine